Clinical trial

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

NCT02905591

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2018-11-16

PhasePHASE2

Study timeline

Study start (actual)2018-11-16Date precision: day

Registry last updated2026-07-31

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Carcinoma, Non-Small-Cell Lungcandidate · MONDO: non-small cell lung carcinoma

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Nonsmall Cell Lung Cancerverified · MONDO: tumor suppressor gene on chromosome 11

Non-Small-Cell Lung Carcinomacandidate · MONDO: non-small cell lung carcinoma

NSCLCverified · MONDO: non-small cell lung carcinoma

Interventions

Radiation TherapyDRUG

PaclitaxelDRUG · verified · RxNorm: paclitaxel

CarboplatinDRUG · verified · RxNorm: carboplatin

Ascorbic AcidDRUG · verified · RxNorm: ascorbic acid

Sponsors & collaborators

Joseph J. Cullen, MD, FACSlead sponsor

National Institutes of Health (NIH)collaborator

National Cancer Institute (NCI)collaborator

Holden Comprehensive Cancer Centercollaborator

Mapped research locations

Iowa CityIowa, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02905591 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.